Should You Buy Portage Biotech Inc (PRTG) Stock After it Has Fallen 28.57% in a Week?

Portage Biotech Inc (PRTG) stock is down 28.57% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Portage Biotech Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PRTG!

See Full PRTG Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PRTG Stock Today?

Portage Biotech Inc (PRTG) stock is trading at $1.30 as of 10:46 AM on Monday, Jan 8, a rise of $0.20, or 18.81% from the previous closing price of $1.09. The stock has traded between $1.17 and $1.39 so far today. Volume today is high. So far 85,437 shares have traded compared to average volume of 43,187 shares.

More About Portage Biotech Inc

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. Click Here to get the full Stock Report for Portage Biotech Inc stock.